THANK YOU FOR SUBSCRIBING
MediciNova's MN-166 (ibudilast) in amyotrophic lateral sclerosis had been accepted for presentation at the 32nd International Symposium on ALS or MND.
FREMONT, CA: MediciNova, Inc., a biopharmaceutical organization listed on the NASDAQ Global Market and the Tokyo Stock Exchange's JASDAQ Market (Code Number: 4875), recently announced that an abstract for MediciNova's current Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) had been acknowledged for presentation at the 32nd International Symposium on ALS or MND (amyotrophic lateral sclerosis or motor neuron disease) which will be held on December 7 - 10, 2021.
Kazuko Matsuda, M.D. Ph.D. M.P.H., Chief Medical Officer, MediciNova, Inc., will give a speech headlined "COMBAT-ALS Phase 2b/3 Trial of MN-166 (ibudilast) in ALS: Trial Update." Details about the presentation will be released as they become available.
"We are very pleased to present ongoing activities from the COMBAT-ALS trial at the 32nd International Symposium on ALS/MND. The purpose of presenting at this symposium attended by ALS/MND researchers, clinicians, and patients is to share information about this important trial to a greater number of stakeholders in the ALS community. We want to express our deep gratitude to patients who volunteer to participate in our trial, as well as those who conduct the trial at their fine institutions," commented Dr. Yuichi Iwaki, M.D. Ph.D., President and Chief Executive Officer, MediciNova, Inc.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group research in patients with ALS to assess the effectiveness, safety, and tolerability of MN-166 (ibudilast) accompanied by an open-label extension phase (6 months). It is scheduled to recruit 230 people at 30 locations across the United States, Canada, and Europe (NCT04057898). Patients who meet the entrance criteria will be allocated 1:1 to two treatment groups: MN-166 (ibudilast) 100 mg/day or a matching placebo. Change in ALSFRS-R score from baseline at Month 12 (or last observation before death in case of censoring) and survival time is the primary endpoints.